GANIRELIX ACETATE Drug Patent Profile

Which patents cover Ganirelix Acetate, and when can generic versions of Ganirelix Acetate launch?

Ganirelix Acetate is a drug marketed by Amphastar Pharms Inc, Gland, Lupin Ltd, Meitheal, Organon Usa Organon, Qilu, and Tris Pharma Inc. and is included in seven NDAs.

The generic ingredient in GANIRELIX ACETATE is ganirelix acetate. There are four drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the ganirelix acetate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ganirelix Acetate

A generic version of GANIRELIX ACETATE was approved as ganirelix acetate by ORGANON USA ORGANON on July 29^th, 1999.

Summary for GANIRELIX ACETATE

US Patents:	0
Applicants:	7
NDAs:	7
Finished Product Suppliers / Packagers:	9
Raw Ingredient (Bulk) Api Vendors:	37
Clinical Trials:	23
Patent Applications:	135
Drug Prices:	Drug price information for GANIRELIX ACETATE
What excipients (inactive ingredients) are in GANIRELIX ACETATE?	GANIRELIX ACETATE excipients list
DailyMed Link:	GANIRELIX ACETATE at DailyMed

See drug prices for GANIRELIX ACETATE

Recent Clinical Trials for GANIRELIX ACETATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Institute on Aging (NIA)	PHASE4
University of Delaware	PHASE4
Instituto Bernabeu	Phase 4

See all GANIRELIX ACETATE clinical trials

Pharmacology for GANIRELIX ACETATE

Drug Class	Gonadotropin Releasing Hormone Receptor Antagonist
Mechanism of Action	Gonadotropin Releasing Hormone Receptor Antagonists
Physiological Effect	Decreased GnRH Secretion

Anatomical Therapeutic Chemical (ATC) Classes for GANIRELIX ACETATE

H01CC	Anti-gonadotropin-releasing hormones
H01C	HYPOTHALAMIC HORMONES
H01	PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES
H	Systemic hormonal preparations, excluding sex hormones and insulins

Paragraph IV (Patent) Challenges for GANIRELIX ACETATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
GANIRELIX ACETATE	Injection	ganirelix acetate	250 mcg/0.5 mL, 1 mL PFS	021057	1	2012-03-30

US Patents and Regulatory Information for GANIRELIX ACETATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amphastar Pharms Inc	GANIRELIX ACETATE	ganirelix acetate	INJECTABLE;INJECTION	212613-001	Apr 7, 2022	AP	RX	No	No
Tris Pharma Inc	GANIRELIX ACETATE	ganirelix acetate	INJECTABLE;INJECTION	219454-001	Jun 27, 2025		DISCN	No	No
Meitheal	GANIRELIX ACETATE	ganirelix acetate	INJECTABLE;INJECTION	214996-001	Jun 6, 2022	AP	RX	No	No
Gland	GANIRELIX ACETATE	ganirelix acetate	INJECTABLE;INJECTION	215658-001	Feb 28, 2023	AP	RX	No	No

Expired US Patents for GANIRELIX ACETATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Organon Usa Organon	GANIRELIX ACETATE	ganirelix acetate	INJECTABLE;INJECTION	021057-001	Jul 29, 1999	6,653,286
Organon Usa Organon	GANIRELIX ACETATE	ganirelix acetate	INJECTABLE;INJECTION	021057-001	Jul 29, 1999	4,801,577
Organon Usa Organon	GANIRELIX ACETATE	ganirelix acetate	INJECTABLE;INJECTION	021057-001	Jul 29, 1999	5,767,082

International Patents for GANIRELIX ACETATE

See the table below for patents covering GANIRELIX ACETATE around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	1339043	ANALOGUES NONAPEPTIDIQUES ET DECAPEPTIDIQUES DE LHRH, UTILES COMME ANTAGONISTES DE LHRH (NONAPEPTIDE AND DECAPETIDE ANALOGS OF LHRH USEFUL AS LHRH ANTAGONISTS)
Denmark	57288
Ireland	880298
Hungary	T63855

Supplementary Protection Certificates for GANIRELIX ACETATE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0277829	27/2000	Austria		PRODUCT NAME: GANIRELIX ODER PHARMAZEUTISCH ANNEHMBARE SALZE DAVON; REGISTRATION NO/DATE: EU/1/00/130/001-002 20000517
0277829	2000C/030	Belgium		PRODUCT NAME: GANIRELIX; REGISTRATION NO/DATE: EU/1/00/130/001 20000518
0277829	C300016	Netherlands		PRODUCT NAME: GANIRELIX, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; NATL REGISTRATION NO/DATE: EU/1/00/130/001-002 20000517
0277829	SPC/GB00/024	United Kingdom		PRODUCT NAME: GANIRELIX OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/00/130/001 20000517; UK EU/1/00/130/002 20000517

Ganirelix Acetate: Market Dynamics and Financial Trajectory

Last updated: April 25, 2026

What is the commercial positioning of ganirelix acetate?

Ganirelix acetate is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in assisted reproductive technology (ART) to prevent premature luteinizing hormone (LH) surges during controlled ovarian stimulation. The product class sits within a highly regulated, branded/specialty market where utilization depends on clinician protocol choices, payer coverage, and competitor switching within ART clinics.

Commercially, ganirelix acetate is typically sold as a sterile injection solution for subcutaneous administration. In practice, demand tracks ART cycle volumes and protocol preferences for antagonist-based regimens. Because it is a niche within fertility care and administered in short, cycle-based courses, revenue patterns tend to follow clinic throughput and patient volume rather than chronic-market adoption.

How does the market structure affect pricing power and volatility?

The ganirelix acetate market is shaped by four structural forces:

1. Protocol-driven demand concentration
   Use is bounded to ART cycles. When clinics run more antagonist protocols and fewer agonist protocols, uptake rises. When protocols shift, patient volumes can move quickly between products.

2. Biosafety/sterile manufacturing and supply constraints
   Fertility injectables depend on continuous sterile supply chains. Any manufacturing disruption typically creates temporary price and volume dislocation.

3. Generic and “authorized” competition
   The market is exposed to price erosion when additional equivalent products become available or when authorized/brand-to-generic transitions occur in key geographies. Specialty injectables often face steeper net-price declines than oncology or rare-disease biologics.

4. Payer reimbursement and out-of-pocket sensitivity
   Fertility spending is elastic at the margin in many markets. Coverage policies, step therapy, and patient co-pay burden can cause demand swings even if clinical efficacy is stable.

What are the competitive dynamics across ART drug classes?

Ganirelix acetate competes within the broader antagonist toolkit and against alternative stimulation regimens. The main competitive pressures are:

• Other GnRH antagonists used in ART protocols (same clinical endpoint: LH surge suppression).
• GnRH agonist long protocols used in some clinics (different regimen but comparable therapeutic goals in avoiding premature LH rise).
• Differentiation by dosing convenience, pen vs vial format, and clinic familiarity. When a competitor launches an easier-to-administer presentation, clinics can shift procurement even when drug acquisition cost differences are modest.

Net impact: ganirelix acetate tends to show cycle-volume sensitivity with rapid substitution risk at the clinic level if an alternative product is priced more favorably or is preferred by formularies.

How has financial performance likely evolved over time?

A practical financial trajectory for ganirelix acetate in an ART-focused, injection-based niche typically follows this shape:

• Early growth (protocol adoption and market entry)
  Revenue expansion occurs as clinics adopt antagonist protocols and as the product gains formulary presence.

• Mid-cycle plateau (mature adoption)
  As antagonist penetration stabilizes, growth becomes incremental, driven by ART volume trends and minor share changes.

• Late-stage margin compression (competition and reimbursement pressure)
  Once additional versions enter the market in major geographies, net pricing typically declines. A drop in gross margin is common even if unit volumes hold, because fertility injectables face aggressive contracting and tender pricing.

This profile is consistent with how many established fertility injectables behave: stable demand base, but sustained net-price pressure once equivalents expand.

What drives revenue in ganirelix acetate: volume or price?

For ganirelix acetate, revenue is usually dominated by units per cycle multiplied by net price plus competitive share shifts. In practical terms:

• Unit volume tracks ART cycle counts and clinic adoption of antagonist protocols.
• Net price is shaped by tendering, payer contracts, pharmacy benefit design (where applicable), and competition from other antagonists and equivalents.

In mature markets, price effects usually dominate. In growth phases, volume can dominate. The market’s substitution risk means that procurement decisions can swing share quickly, so even small price advantages can move prescription patterns.

What is the financial trajectory by life-cycle stage?

The likely trajectory is life-cycle-dependent:

• Pre-competition / single-brand period: higher net pricing, stable margins, and share gains through formulary access.
• Multi-brand period: price negotiations intensify; revenue may still grow modestly if antagonist protocols keep expanding.
• Equivalent-entry period: net price erosion accelerates; revenue often flattens unless the product retains strong clinic preference.
• Maturity: product-specific growth depends on contract renewals, supply reliability, and presentation convenience rather than innovation.

What market signals matter for near-term financial outcomes?

Near-term financial trajectory is most sensitive to:

• ART procedure volumes in target geographies
• Clinic formulary changes triggered by price tender cycles
• Reimbursement coverage updates for fertility injectables
• Supply stability (sterile manufacturing uptime and distribution execution)
• Competition announcements tied to launches or authorized manufacturing

When demand growth outpaces supply constraints, pricing can strengthen temporarily. When competition or equivalent entry increases, net price declines typically outweigh unit stabilization.

How does regulatory status shape the market?

Ganirelix acetate is subject to regulatory and post-marketing requirements typical for sterile injectable products. Market access depends on maintaining current Good Manufacturing Practice compliance, stable distribution, and label compliance for ART protocols.

Regulatory posture also shapes entry timing for competitive products, which affects when pricing pressure begins.

What does the competitive and lifecycle landscape imply for investors or R&D planners?

For a branded fertility injectable like ganirelix acetate, competitive entry and reimbursement behavior dominate the financial story. Any development or investment thesis should treat the market as:

• High share-sensitivity at the clinic level
• Meaningfully exposed to tender and contracting
• Demand-tethered to ART volumes
• Low innovation tailwind compared with breakthrough therapeutic categories

Market dynamics and financial trajectory summary (condensed)

Dimension	Typical impact on ganirelix acetate finances
ART cycle volumes	Drives unit growth/decline
GnRH antagonist protocol penetration	Determines addressable patient volume
Net price via tenders/formularies	Primary driver of margin compression in mature stages
Substitution among antagonists	Rapid share shifts; revenue volatility at tender dates
Supply stability	Temporary price spikes if constrained; revenue loss if shortages occur
Equivalent entry	Accelerates net price erosion and flattens growth

Key Takeaways

• Ganirelix acetate demand is cycle-driven and tracks ART procedure volumes and antagonist protocol adoption.
• Revenue and margin are most sensitive to net price outcomes from tendering and payer contracting once competitive alternatives or equivalents expand.
• The financial trajectory typically follows a pattern of early adoption growth, maturity plateau, then sustained margin compression as competition increases.
• Near-term performance is driven by clinic formulary retention, supply reliability, and reimbursement coverage rather than clinical differentiation alone.

FAQs

1) Is ganirelix acetate primarily a growth or value product?
It behaves like a value and stability-oriented specialty product in a cycle-based market where net price and share retention dominate outcomes.

2) What most influences quarterly revenue changes for ganirelix acetate?
ART cycle volume fluctuations and contract or tender-driven net price changes.

3) How does clinic substitution risk impact long-term margins?
Substitution among GnRH antagonists can accelerate share loss, pushing net pricing down and compressing margins.

4) What supply factors can alter the financial trajectory?
Sterile manufacturing disruptions or distribution constraints can temporarily raise realized prices but can also reduce fill rates, hurting revenue.

5) Does reimbursement strongly affect utilization?
Yes, fertility coverage rules and patient cost-sharing can shift demand even when clinical protocols remain stable.

---

References

[1] European Medicines Agency (EMA). Ganirelix acetate: EPAR product information and related assessment documents. EMA.
[2] U.S. Food and Drug Administration (FDA). Drug Approval Package and labeling for ganirelix acetate (and related products where applicable). FDA.
[3] PubMed. GnRH antagonist use in assisted reproduction and clinical protocol reviews involving ganirelix acetate. National Library of Medicine.